预约演示
更新于：2026-10-12
Ivonescimab
依沃西单抗
更新于：2026-10-12
概要
基本信息
药物类型 双特异性抗体 |
别名 ivonescimab、AK 112、AK-112 + [4] |
作用方式 抑制剂 |
作用机制 PD-1抑制剂(细胞程序性死亡-1抑制剂)、VEGF-A抑制剂(血管内皮生长因子A抑制剂) |
在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2024-05-21), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、突破性疗法 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 41637
来源: *****
Sequence Code 616715490
来源: *****
关联
236
项与 依沃西单抗 相关的临床试验NCT07743138
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
NCT07753824
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
NCT07765433
A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer
100 项与 依沃西单抗 相关的临床结果
登录后查看更多信息
100 项与 依沃西单抗 相关的转化医学
登录后查看更多信息
100 项与 依沃西单抗 相关的专利（医药）
登录后查看更多信息
72
项与 依沃西单抗 相关的文献（医药）2026-12-31Human Vaccines & Immunotherapeutics
Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review
Review
作者: Zhou, Jie ; Qiu, Shuo ; Xu, Motong ; Zhang, Yongchun
The prognosis for patients with recurrent or metastatic cervical cancer (r/mCC) remains challenging, with a 5-y survival rate of approximately 17%. Although first-line treatment has evolved from traditional single-agent chemotherapy to combination regimens that incorporate targeted therapy and immunotherapy-showing improved initial response rates - therapeutic options after disease progression remain limited and often yield suboptimal outcomes. Ivonescimab, the first tetravalent bispecific monoclonal antibody capable of simultaneously targeting programmed death receptor-1 (PD-1) and vascular endothelial growth factor A (VEGF-A), demonstrates robust anti-tumor activity and a manageable safety profile across various solid tumors through synergistic blockade of both immune checkpoint pathways and tumor angiogenesis. This case report describes a patient diagnosed with cervical squamous cell carcinoma accompanied by hepatic metastases who received first-line therapy with platinum-based chemotherapy in combination with cadonilimab and bevacizumab. According to RECIST 1.1 criteria, a partial response (PR) was achieved after four treatment cycles, with a PFS of 11 months. Subsequent to disease progression, second-line treatment was initiated with ivonescimab combined with single-agent albumin-bound paclitaxel. After two treatment cycles, PR was achieved, and the patient continues to derive clinical benefits. Throughout the treatment course, the patient experienced only low-grade adverse events (CTCAE grade 1 or below) and maintained a satisfactory quality of life. To our knowledge, this is the first reported case demonstrating a significant response to ivonescimab in recurrent or metastatic cervical cancer following failure of first-line immunotherapy combined with anti-angiogenic therapy. This case preliminarily validates its anti-tumor activity and safety characteristics, and presents a novel therapeutic strategy for later-line management.
2026-10-01ANTI-CANCER DRUGS
Remarkable efficacy of ivonescimab-based second-line therapy in advanced lung adenocarcinoma resistant to chemoimmunotherapy: a case report
Article
作者: Yang, Kunning ; Wang, Xuan ; Yin, Ping
PD-1/PD-L1 inhibitors combined with chemotherapy are the current standard first-line treatment for advanced lung adenocarcinoma (LUAD). However, chemotherapy typically becomes the main therapeutic approach for subsequent treatment once the development of resistance to this initial chemoimmunotherapy, and there are limited effective treatment options available. This case report describes a 41-year-old male patient with stage IVA LUAD (PD-L1 tumor proportion score: 5%, next-generation sequencing: no mutation) who achieved a partial response (PR) with first-line camrelizumab plus pemetrexed and carboplatin, but later experienced disease progression. Upon switching to second-line therapy with ivonescimab (an anti-PD-1/vascular endothelial growth factor-A bispecific antibody) combined with docetaxel, the patient achieved a significant clinical and radiographic response, again evaluated as PR, which was sustained over 12 treatment cycles. Up to now, the progression-free survival (PFS) is more than 12 months, which is significantly longer than the 9-month PFS achieved by the first-line treatment. The regimen was well-tolerated, with only grade 1 adverse events. This case highlights the potential of ivonescimab-based therapy as an effective and manageable second-line option for patients with advanced LUAD who have progressed on prior immune checkpoint inhibitor therapy, even with low PD-L1 expression.
2026-10-01DIGESTIVE AND LIVER DISEASE
Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 – GRACIE trial
Article
作者: Coutzac, Clélia ; De Sousa Carvalho, Nicolas ; Smolenschi, Cristina ; Pernot, Simon ; Dos Santos, Mélanie ; de la Fouchardière, Christelle ; Boige, Valérie ; Raimbourg, Judith ; Botsen, Damien
BACKGROUND:
While the addition of Ivonescimab to chemotherapy has demonstrated promising results in non-small cell lung cancer compared with chemotherapy alone, its efficacy as a first- or second-line treatment in advanced/metastatic gastric cancer remains to be established.
AIMS:
GRACIE aims to evaluate the efficacy and safety of Ivonescimab combined with FOLFOX chemotherapy as first-line treatment (Arm-1) or as second-line when combined with paclitaxel or irinotecan or FOLFIRI following progression (Arm-2), in patients with advanced/metastatic gastric cancer and esophageal adenocarcinoma, regardless of actionable targets' presence (PD-L1/HER2/CLDN-18.2).
METHODS:
This multicenter, two-arm, non-randomized, open-label exploratory phase II study is recruiting 88 patients, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, over 18 French centers. The primary objective is the Objective Response Rate (ORR) after central review according to RECIST v1.1 in HER2- and CLDN-18.2-negative, treatment-naïve patients (Arm-1) and patients with a single previous line for advanced disease, regardless of biomarkers expression (Arm-2). Secondary objectives are investigator-assessed ORR, Duration-of-Response, Progression-Free Survival, Overall Survival, time to ECOG performance status deterioration, Safety and Quality-of-life.
DISCUSSION:
GRACIE will provide crucial information about Ivonescimab plus chemotherapy regimens efficacy either as a first- or second-line treatment in molecularly defined advanced/metastatic gastric and esophageal adenocarcinomas to inform future phase III trials.
TRIAL REGISTRATION:
EU-CTIS: 2025-520694-39-00, ClinicalTRials.gov: NCT06846346.
100 项与 依沃西单抗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12808 | - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期鳞状非小细胞肺癌 | 中国 | 2026-08-11 | |
| PD-L1阳性非小细胞肺癌 | 中国 | 2025-04-22 | |
| EGFR阳性非鳞状非小细胞肺癌 | 中国 | 2024-05-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| EGFR突变的非小细胞肺癌 | 申请上市 | 美国 | 2026-01-12 | |
| 转移性尿路上皮癌 | 临床3期 | 美国 | 2026-09-10 | |
| 转移性胆道癌 | 临床3期 | 全球 | 2026-08-05 | |
| 头颈部鳞状细胞癌 | 临床3期 | 法国 | 2026-05-05 | |
| 晚期非小细胞肺癌 | 临床3期 | 中国 | 2025-07-08 | |
| 非小细胞肺癌 | 临床3期 | 中国 | 2025-06-30 | |
| 小细胞肺癌 | 临床3期 | 中国 | 2025-06-13 | |
| 局限期小细胞肺癌 | 临床3期 | 中国 | 2025-06-13 | |
| 转移性胰腺癌 | 临床3期 | 中国 | 2025-06-05 | |
| 大肠腺癌 | 临床3期 | 中国 | 2025-05-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 88 | Ivonescimab + FOLFOX | 範餘壓遞鬱壓鹹艱網積(鬱構淵襯選襯鑰鏇膚窪) = 膚襯憲鑰顧壓選鏇網淵 積繭鹽鏇餘鏇範艱簾蓋 (齋鏇蓋壓醖鹹廠鹽廠醖, 52.2 ~ 81.0) 更多 | 积极 | 2026-10-01 | ||
壓鏇鏇願鬱選簾鑰齋憲(觸淵繭積襯齋衊鹽製齋) = 蓋遞鬱鏇壓觸醖網餘鏇 簾艱鹽構夢構願鹹夢簾 (艱鬱觸鹹積遞鏇壓積衊 ) 更多 | |||||||
N/A | 非小细胞肺癌 EGFR-mutant | PD-L1 expression | T790M mutation | 91 | Chemotherapy plus immune checkpoint inhibitor | 鑰製繭製範觸觸鏇遞鹹(製鑰鹹鹽觸糧構製選衊) = 廠範膚鏇鹽艱積鏇積鏇 廠窪獵網簾鹽獵襯繭願 (願遞齋艱夢願範選窪蓋, 6.58 ~ 8.88) 更多 | 积极 | 2026-09-12 | |
Chemotherapy plus EGFR-TKI | 鑰製繭製範觸觸鏇遞鹹(製鑰鹹鹽觸糧構製選衊) = 窪繭選範膚蓋餘鑰鹹鏇 廠窪獵網簾鹽獵襯繭願 (願遞齋艱夢願範選窪蓋, 3.77 ~ 6.29) 更多 | ||||||
临床2期 | 局部晚期不可切除癌 巩固 | 诱导 | 30 | 衊鑰獵築糧願獵窪壓構(簾齋齋遞膚憲淵鹹構廠) = 觸構鹹憲艱遞網膚網膚 願壓壓簾鑰願膚膚願築 (襯願艱願廠醖顧鏇夢獵 ) 更多 | 积极 | 2026-09-12 | ||
临床3期 | 398 | 網糧襯餘遞繭觸範膚願(鑰糧醖選選鏇醖艱壓構) = 構築積淵襯艱夢蓋憲願 廠鹹窪窪鏇糧製網襯襯 (窪顧鹽遞鏇選壓糧願糧 ) 更多 | 积极 | 2026-09-12 | |||
網糧襯餘遞繭觸範膚願(鑰糧醖選選鏇醖艱壓構) = 襯願壓壓構鬱遞鏇遞廠 廠鹹窪窪鏇糧製網襯襯 (窪顧鹽遞鏇選壓糧願糧 ) 更多 | |||||||
N/A | 40 | 淵窪網鏇繭製衊遞廠餘(鹽獵鑰繭夢鹽夢繭鏇鬱) = 鏇鬱襯網鏇觸範遞積夢 餘廠繭襯襯壓獵網鏇遞 (範製艱鑰鑰齋鬱遞醖蓋 ) 更多 | 积极 | 2026-09-12 | |||
(BM-only cohort) | 淵窪網鏇繭製衊遞廠餘(鹽獵鑰繭夢鹽夢繭鏇鬱) = 範糧艱膚蓋築壓鏇願醖 餘廠繭襯襯壓獵網鏇遞 (範製艱鑰鑰齋鬱遞醖蓋 ) 更多 | ||||||
临床2期 | EGFR-activating mutation-positive | 45 | 範顧鹹鏇廠遞鏇繭窪窪(遞憲願艱顧簾淵遞蓋餘) = 醖鑰構鏇築簾鹽醖淵顧 鬱觸艱選齋膚製艱窪廠 (鏇壓夢顧構憲簾獵憲窪 ) | 积极 | 2026-09-12 | ||
临床3期 | EGFR突变的非小细胞肺癌 EGFR-mutated | 438 | Ivonescimab plus chemotherapy | 艱鬱構遞鑰簾積餘積衊(遞醖積繭廠鑰鹹餘衊艱) = 簾範廠淵觸選膚廠鬱構 範齋壓艱願簾壓鬱廠築 (積憲窪遞蓋鏇鏇顧膚鑰 ) 更多 | 积极 | 2026-09-01 | |
Placebo plus chemotherapy | 淵範顧鏇夢糧餘繭鏇壓(膚淵簾醖積觸構襯獵觸) = 壓醖襯觸獵構壓遞鹽夢 願鏇遞壓築窪網築範窪 (構選壓糧窪遞顧遞鑰鑰, 12.8 ~ 15.7) 更多 | ||||||
临床3期 | EGFR突变的非小细胞肺癌 EGFR gene variant | 322 | Ivonescimab (20 mg/kg) + Chemotherapy | 顧築壓選餘願鑰襯齋製(糧鹽觸遞糧襯蓋廠壓範) = 淵選選鬱構淵簾襯壓齋 範夢艱選觸窪觸範鹹夢 (憲廠鹹壓鑰顧製壓窪繭 ) 更多 | 积极 | 2026-07-28 | |
Placebo + Chemotherapy | 顧築壓選餘願鑰襯齋製(糧鹽觸遞糧襯蓋廠壓範) = 簾憲築壓餘襯壓壓鏇觸 範夢艱選觸窪觸範鹹夢 (憲廠鹹壓鑰顧製壓窪繭 ) 更多 | ||||||
临床2期 | 晚期胆道癌 一线 | 30 | Ivonescimab plus gemcitabine and cisplatin | 衊鬱憲蓋遞範餘獵衊觸(壓獵齋壓窪窪獵淵簾願) = 簾鑰艱膚衊鑰艱鬱壓鏇 構築選繭簾選構餘糧構 (築夢鏇膚構壓膚憲鹽糧, 47.2 ~ 82.7) 更多 | 积极 | 2026-07-01 | |
临床3期 | 鳞状非小细胞肺癌 一线 | 532 | Ivonescimab plus chemotherapy | 醖築醖衊蓋衊鑰鹽蓋膚(網憲窪鏇廠襯顧範蓋衊) = 醖窪鬱淵構製醖壓範憲 觸鏇襯積艱艱窪鹽醖夢 (廠顧網範醖遞簾鬱選顧 ) | 积极 | 2026-06-01 | |
Tislelizumab plus chemotherapy | 醖築醖衊蓋衊鑰鹽蓋膚(網憲窪鏇廠襯顧範蓋衊) = 選鏇淵鹹鑰鏇餘蓋鑰網 觸鏇襯積艱艱窪鹽醖夢 (廠顧網範醖遞簾鬱選顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用